Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An Overview
Open Access
Abstract
Diffuse astrocytomas are the most aggressive and lethal glial tumors of the central nervous system (CNS). Their high cellular heterogeneity and the presence of specific barriers, i.e., blood–brain barrier (BBB) and tumor barrier, make these cancers poorly responsive to all kinds of currently available therapies. Standard therapeutic approaches developed to prevent astrocytoma progression, such as chemotherapy and radiotherapy, do not improve the average survival of patients. However, the recent identification of key genetic alterations and molecular signatures specific for astrocytomas has allowed the advent of novel targeted therapies, potentially more efficient and characterized by fewer side effects. Among others, peptides have emerged as promising therapeutic agents, due to their numerous advantages when compared to standard chemotherapeutics. They can be employed as (i) pharmacologically active agents, which promote the reduction of tumor growth; or (ii) carriers, either to facilitate the translocation of drugs through brain, tumor, and cellular barriers, or to target tumor-specific receptors. Since several pathways are normally altered in malignant gliomas, better outcomes may result from combining multi-target strategies rather than targeting a single effector. In the last years, several preclinical studies with different types of peptides moved in this direction, providing promising results in murine models of disease and opening new perspectives for peptide applications in the treatment of high-grade brain tumors.Keywords
This publication has 81 references indexed in Scilit:
- Evolutionary etiology of high-grade astrocytomasProceedings of the National Academy of Sciences, 2013
- Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and MetastasesPLOS ONE, 2013
- The role of the CXCR4 cell surface chemokine receptor in glioma biologyJournal of Neuro-Oncology, 2013
- Cancer Treatment Using Peptides: Current Therapies and Future ProspectsJournal of Amino Acids, 2012
- A New Phage-Display Tumor-Homing Peptide Fused to Antiangiogenic Peptide Generates a Novel Bioactive Molecule with Antimelanoma ActivityMolecular Cancer Research, 2011
- Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasionOncogene, 2010
- Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug CandidatesGenes & Cancer, 2010
- Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion proteinNature Biotechnology, 2009
- Discovering and improving novel peptide therapeuticsCurrent Opinion in Pharmacology, 2008
- β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary TumorigenesisCell, 2006